# Numiera Therapeutics

Source: https://onco.cc/companies/numiera-therapeutics/  
OnCo record `numiera-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Numiera Therapeutics is a Colorado company repurposing etomoxir, an older heart-failure drug, to cut off the fat-burning energy supply that glioblastoma cells rely on. It holds an FDA orphan designation for malignant glioma.

## Summary

Numiera Therapeutics develops small molecules aimed at cancer cell metabolism, with glioblastoma as its primary indication. Its lead asset is etomoxir, an inhibitor of carnitine palmitoyltransferase 1 (CPT1) first tested in congestive heart failure, which the company is repurposing to block fatty acid oxidation in glioma cells. The FDA designated etomoxir an orphan drug for the treatment of malignant glioma on 12 November 2024, with Numiera as sponsor. In fiscal year 2026 NCI awarded it USD 1,204,195 under SBIR award 1R44CA310352-01 for etomoxir in recurrent glioblastoma; the company announced the award in September 2026 as funding for its clinical trials.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Numiera Therapeutics Inc; Numiera Therapeutics, Inc.
- HQ: Denver, CO
- Type: biotech
- Website: https://www.numiera.com/

## Notes

- The FDA orphan record gives the sponsor's address as Fort Collins, Colorado; NIH RePORTER and the company website give Denver. Read on numiera.com, the FDA Orphan Drug Designations database and NIH RePORTER on 4 November 2026. No CPT1 target record exists in the corpus.

## Sources

- Official website: https://www.numiera.com/
- Numiera Therapeutics: etomoxir: https://www.numiera.com/etomoxir
- NIH RePORTER: SBIR award 1R44CA310352-01: https://reporter.nih.gov/project-details/11314195

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Metabolic therapy: starving the tumour of a nutrient](https://onco.cc/technologies/metabolic-therapy/)
- drugs: [Etomoxir](https://onco.cc/drugs/etomoxir/)

---
JSON: https://onco.cc/api/v1/entities/numiera-therapeutics.json